Teva Moves On From Restructuring To Improving Margins

As Israeli Firm Sees Mixed Impact From COVID-19 Pandemic

Teva has expanded on plans to improve its profit margins after emerging from a years-long restructuring program that has cut its cost base by over $3bn. The Israeli company reported first-quarter sales ahead by 5% to $4.36bn, seeing a “mixed bag” effect from the COVID-19 pandemic as well as positive results from new launches including two US biosimilars.

Margin
Teva is keeping a close eye on its profit margins • Source: Shutterstock

Teva has set out more details of how it plans to improve its profit margins in the wake of an extensive restructuring of the business, as the firm has reported a mixed impact from the COVID-19 pandemic in the first quarter of 2020.

Having at the end of 2019 celebrated the completion of a long-term restructuring plan – with measures that included cutting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By 

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.

Xbrane Sets Date For Latest Run At Ranibizumab In US

 
• By 

After a series of setbacks for its Lucentis (ranibizumab) biosimilar filing in the US, Xbrane Biopharma now has a fresh action date from the FDA – although any approval will be contingent on a successful agency reinspection of its manufacturing sites.

Zydus Strikes Landmark $141m Agreement To Break Into Global CDMO Business

 
• By 

Zydus Lifesciences said it would be able to leverage supply chain dynamics and a “favorable geopolitical environment” to expand its reach in the US and globally as it penned a trio of agreements to plant its flag in the global CDMO space.

More from Business

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By 

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

Formycon And Fresenius Launch Partnered Stelara Rival In Canada

 
• By 

Several years after the initial signing of their agreement, Formycon and Fresenius Kabi announced the launch of their Stelara biosimilar Otulfi in Canada, adding another key market to their list.

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By 

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.